Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 16(5): e0250525, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33945553

RESUMO

Klebsiella pneumoniae is a major pathogen implicated in nosocomial infections. Extended-spectrum ß-lactamase (ESBL)-producing K. pneumoniae isolates are a public health concern. We aim to characterize the type of ß-lactamases and the associated resistance mechanisms in ESBL-producing K. pneumoniae isolates obtained from blood cultures in a Portuguese hospital, as well as to determine the circulating clones. Twenty-two cefotaxime/ceftazidime-resistant (CTX/CAZR) K. pneumoniae isolates were included in the study. Identification was performed by MALDI-TOF MS and the antimicrobial susceptibility testing by disk-diffusion. The screening test for ESBL-production was performed and ESBL-producer isolates were further characterized. The presence of different beta-lactamase genes (blaCTX-M, blaSHV, blaTEM, blaKPC, blaNDM, blaVIM, blaOXA-48, blaCMY-2, blaDHA-1, blaFOX, blaMOX, and blaACC) was analyzed by PCR/sequencing in ESBL-producer isolates, as well as the presence of other resistance genes (aac(6')-Ib-cr, tetA/B, dfrA, qnrA/B/S, sul1/2/3) or integron-related genes (int1/2/3). Multilocus-sequence-typing (MLST) was performed for selected isolates. ESBL activity was detected in 12 of the 22 CTX/CAZR K. pneumoniae isolates and 11 of them carried the blaCTX-M-15 gene (together with blaTEM), and the remaining isolate carried the blaSHV-106 gene. All the blaCTX-M-15 harboring isolates also contained a blaSHV gene (blaSHV-1, blaSHV-11 or blaSHV-27 variants). Both blaSHV-27 and blaSHV-106 genes correspond to ESBL-variants. Two of the CTX-M-15 producing isolates carried a carbapenemase gene (blaKPC2/3 and blaOXA-48) and showed imipenem resistance. The majority of the ESBL-producing isolates carried the int1 gene, as well as sulphonamide-resistance genes (sul2 and/or sul3); the tetA gene was detected in all eight tetracycline-resistant isolates. Three different genetic lineages were found in selected isolates: ST348 (one CTX-M-15/TEM/SHV-27/KPC-2/3-producer isolate), ST11 (two CTX-M-15/TEM/SHV-1- and CTX-M-15-TEM-SHV-11-OXA-48-producer isolates) and ST15 (one SHV-106/TEM-producer isolate). ESBL enzymes of CTX-M-15 or SHV-type are detected among blood K. pneumoniae isolates, in some cases in association with carbapenemases of KPC or OXA-48 type.


Assuntos
Cefotaxima/uso terapêutico , Ceftazidima/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/genética , Sepse/patologia , beta-Lactamases/genética , Antibacterianos/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/genética , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Humanos , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/genética , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/efeitos dos fármacos , Klebsiella pneumoniae/isolamento & purificação , Testes de Sensibilidade Microbiana , Tipagem de Sequências Multilocus/métodos , Sepse/tratamento farmacológico , Sepse/genética , Sepse/microbiologia , Análise de Sequência de DNA/métodos
2.
Sci Rep ; 10(1): 4438, 2020 03 10.
Artigo em Inglês | MEDLINE | ID: mdl-32157186

RESUMO

The purpose of this study was to evaluate risk factors of Clostridium Difficile infection (CDI) after spinal surgery using the Health Insurance Review and Assessment Service (HIRA) data. The incidence of postoperative CDI was investigated using HIRA data from 2012 to 2016. Cases involving CDI that occurred within a 30-day postoperative period were identified. Risk factors, including age, sex, comorbidities, postoperative infection, spinal surgery procedure, type of antibiotic, and duration of antibiotic use, were evaluated. Duration of hospital stay, medical cost, and mortality were also evaluated. In total, 71,322 patients were included. Presumed cases of CDI were identified in 57 patients, with CDI rate of 0.54 per 10,000 patient days. Advanced age, staged operation, postoperative infection, and the use of multiple antibiotics were significant risk factors. First-generation cephalosporins were shown to be associated with a lower incidence of CDI. CDI was also associated with longer hospital stays and increased medical cost, and it was an independent risk factor for increased mortality. Extra attention should be paid to patients at high risk for the development of postoperative CDI, and unnecessary use of multiple antibiotics should be avoided. Level of Evidence: Level III, retrospective cohort study.


Assuntos
Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/etiologia , Infecção Hospitalar/etiologia , Bases de Dados Factuais , Procedimentos Neurocirúrgicos/efeitos adversos , Complicações Pós-Operatórias/etiologia , Doenças da Coluna Vertebral/cirurgia , Adolescente , Adulto , Idoso , Antibacterianos/administração & dosagem , Criança , Pré-Escolar , Infecções por Clostridium/tratamento farmacológico , Infecções por Clostridium/patologia , Comorbidade , Infecção Hospitalar/patologia , Feminino , Humanos , Lactente , Recém-Nascido , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde , Complicações Pós-Operatórias/patologia , Estudos Retrospectivos , Fatores de Risco , Doenças da Coluna Vertebral/patologia , Adulto Jovem
3.
Artigo em Inglês | MEDLINE | ID: mdl-28971876

RESUMO

The aim of the current study was to compare community-acquired acute pyelonephritis (CA-APN) with health care-associated acute pyelonephritis (HCA-APN), describe the outcomes, and identify variables that could predict antimicrobial susceptibility. We conducted an observational study that included all consecutive episodes of acute pyelonephritis (APN) in adults during 2014 at a Spanish university hospital. From each episode, demographic data, comorbidities, clinical presentation, microbiological data, antimicrobial therapy, and outcome were recorded. A multivariable logistic regression model was performed to define the variables associated with antimicrobial resistance. A total of 607 patients, 503 (82.9%) with CA-APN and 104 (17.1%) with HCA-APN, were included in the study. Patients with HCA-APN were older than patients with CA-APN (70.4 versus 50.6 years; P < 0.001) and had higher rates of previous urinary tract infections (UTIs) (56.5% versus 24.5%; P < 0.001) and previous antibiotic use (56.8% versus 22.8%; P < 0.001). Escherichia coli was more frequently isolated from patients with CA-APN than from patients with HCA-APN (79.9% versus 50.5%; P < 0.001). The rates of resistance of Escherichia coli strains from CA-APN patients versus HCA-APN patients were as follows: amoxicillin-clavulanic acid, 22.4% versus 53.2% (P = 0.001); cefuroxime, 7.7% versus 43.5% (P = 0.001); cefotaxime, 4.3% versus 32.6% (P < 0.001); ciprofloxacin, 22.8% versus 74.5% (P < 0.001); and co-trimoxazole, 34.5% versus 58.7% (P = 0.003). The site of acquisition, recurrent UTIs, and previous antibiotic use were independent risk factors for antimicrobial resistance. Relapse rates were significantly higher when definitive antimicrobial treatment was not adequate (37.1% versus 9.3% when definitive antimicrobial treatment was adequate; P < 0.001). Our study reflects the rise of resistance to commonly used antibiotics in acute pyelonephritis. In order to choose the adequate empirical antibiotic therapy, risk factors for resistance should be considered.


Assuntos
Antibacterianos/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Farmacorresistência Bacteriana , Infecções por Escherichia coli/tratamento farmacológico , Escherichia coli/efeitos dos fármacos , Pielonefrite/tratamento farmacológico , Infecções Urinárias/tratamento farmacológico , Doença Aguda , Adulto , Idoso , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Cefotaxima/uso terapêutico , Cefuroxima/uso terapêutico , Ciprofloxacina/uso terapêutico , Estudos de Coortes , Infecções Comunitárias Adquiridas , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Pesquisa Empírica , Escherichia coli/crescimento & desenvolvimento , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/patologia , Feminino , Hospitais Universitários , Humanos , Modelos Logísticos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pielonefrite/microbiologia , Pielonefrite/patologia , Fatores de Risco , Espanha , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Infecções Urinárias/microbiologia , Infecções Urinárias/patologia
4.
Artigo em Inglês | MEDLINE | ID: mdl-28232309

RESUMO

We report a case of infective endocarditis (IE) caused by ceftaroline-resistant, daptomycin-tolerant, and heterogeneous vancomycin-intermediate methicillin-resistant S. aureus (MRSA). Resistance to ceftaroline emerged in the absence of drug exposure, and the E447K substitution in the active site of PBP2a previously associated with ceftaroline resistance was identified. Additionally, we present evidence of patient-to-patient transmission of the strain within the same unit. This case illustrates the difficulties in treating MRSA IE in the setting of a multidrug-resistant phenotype.


Assuntos
Antibacterianos/uso terapêutico , Proteínas de Bactérias/genética , Daptomicina/uso terapêutico , Farmacorresistência Bacteriana Múltipla/genética , Endocardite Bacteriana/tratamento farmacológico , Proteínas de Ligação às Penicilinas/genética , Infecções Estafilocócicas/tratamento farmacológico , Vancomicina/uso terapêutico , Adulto , Substituição de Aminoácidos , Cefalosporinas/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Quimioterapia Combinada , Endocardite Bacteriana/microbiologia , Endocardite Bacteriana/patologia , Expressão Gênica , Humanos , Masculino , Meticilina/uso terapêutico , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/genética , Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento , Testes de Sensibilidade Microbiana , Infecções Estafilocócicas/microbiologia , Infecções Estafilocócicas/patologia , Ceftarolina
5.
Indian J Cancer ; 54(4): 685-690, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-30082559

RESUMO

OBJECTIVE: Carbapenems are one of the last therapeutic options to treat various bacterial infections including multidrug resistant (MDR) nosocomial infections. However, excessive and inappropriate prescription of this drug has recently led to an epidemic rise in carbapenem resistance. Optimizing antibiotic utilization and exploring alternate options can be a potential way to control carbapenem resistance. The aim of this study was to assess the clinical efficacy of novel antibiotic adjuvant entity (ceftriaxone + sulbactam + ethylenediaminetetraacetic acid [EDTA] [CSE-1034]) in the treatment of various nosocomial infections. METHODS: Older patients suffering from hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated urinary tract infections who received CSE-1034 as empirical therapy were evaluated. CSE-1034 therapy was initiated empirically and continued based on the results of culture sensitivity and clinical outcome. RESULTS: In total, 59 culture-positive patients with mean age of 57 ± 19 years were evaluated in this retrospective study. Escherichia coli was the most predominant pathogen isolated, followed by Acinetobacter baumannii, Klebsiella pneumonia, and Pseudomonas aeruginosa. Microbial sensitivity analysis has shown that isolates from all patients exhibited resistance to multiple classes of antibiotics. Isolated pathogens from 78% were sensitive to meropenem, 86% to CSE-1034, and 100% to colistin except Proteus species. Overall assessment of clinical outcome has shown that 83% cases were cured with CSE-1034 monotherapy, 12% with CSE-1034 and colistin combination therapy, and 5% were cured with alternate meropenem therapy. CONCLUSION: From this study, it can be concluded that ceftriaxone + sulbactam + EDTA alone or in combination with colistin can be an effective empiric treatment of various MDR nosocomial infections and can serve as an effective alternative to carbapenems.


Assuntos
Ceftriaxona/administração & dosagem , Infecção Hospitalar/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Sulbactam/administração & dosagem , Acinetobacter baumannii/patogenicidade , Idoso , Ceftriaxona/efeitos adversos , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Feminino , Humanos , Doença Iatrogênica/epidemiologia , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pneumonia Associada à Ventilação Mecânica/microbiologia , Pneumonia Associada à Ventilação Mecânica/patologia , Sulbactam/efeitos adversos
6.
Clin Microbiol Infect ; 20(11): 1205-10, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24888250

RESUMO

Catheter-related bacteraemia (CRB) is a cause of death in hospitalized patients, and parenteral nutrition (PN) is a risk factor. We aim to describe the prognosis of PN-CRB and the impact of catheter extraction within 48 h from bacteraemia. All consecutive hospitalized adult patients with CRB (2007-2012) were prospectively enrolled. Factors associated with 30-day mortality were determined by logistic regression analysis. Among 847 episodes of CRB identified, 291 (34%) episodes were associated with short-term catheter use for PN. Cure was achieved in 236 (81%) episodes, 42 (14.5%) patients died within the first 30 days, 7 (2.5%) relapsed, and 6 (2%) had re-infection. On multivariate analysis, previous immunosuppressive therapy (OR 5.62; 95% CI 1.69-18.68; p 0.0048) and patient age (OR 1.05; 95% CI 1.02-1.07; p 0.0009) were predictors of 30-day mortality, whereas catheter removal within 48 h of bacteraemia onset (OR 0.26; 95% CI 0.12-0.58; p 0.0010) and adequate empirical antibiotic treatment (OR 0.36; 95% CI 0.17-0.77; p 0.0081) were protective factors. Incidence of PN-CRB decreased from 5.36 episodes/1000 days of PN in 2007 to 2.9 in 2012, yielding a 46.1% rate reduction (95% CI 15.7-65.5%), which may be attributable to implementation of a multifaceted prevention strategy. In conclusion, short-term PN-CRB accounted for one-third of all episodes of CRB in our setting, and 14.5% of patients died within 30 days following bacteraemia. Our findings suggest that prompt catheter removal and adequate empirical antibiotic treatment could be protective factors for 30-day mortality. Concomitantly with implementation of a multifaceted prevention strategy, PN-CRB incidence was reduced by half.


Assuntos
Bacteriemia/patologia , Infecções Relacionadas a Cateter/patologia , Infecção Hospitalar/patologia , Nutrição Parenteral/efeitos adversos , Adulto , Idoso , Antibacterianos/uso terapêutico , Bacteriemia/mortalidade , Infecções Relacionadas a Cateter/mortalidade , Estudos de Coortes , Infecção Hospitalar/mortalidade , Feminino , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Análise de Sobrevida , Fatores de Tempo , Suspensão de Tratamento
7.
Eur J Clin Microbiol Infect Dis ; 30(10): 1271-8, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21461847

RESUMO

A total of 118 patients with Elizabethkingia meningoseptica bacteremia at a medical center in Taiwan from 1999 to 2006 were studied. Minimum inhibitory concentrations (MICs) of 99 preserved isolates were determined. The incidence (per 100,000 admissions) of E. meningoseptica bacteremia increased from 7.5 in 1996 to 35.6 in 2006 (p = 0.006). Among them, 84% presented with fever, 86% had nosocomial infections, and 60% had acquired the infection in intensive care units (ICUs). The most common underlying diseases were malignancy (36%) and diabetes mellitus (25%). Seventy-eight percent of patients had primary bacteremia, followed by pneumonia (9%), soft tissue infection, and catheter-related bacteremia (6%). Forty-five patients (38%) had polymicrobial bacteremia. Overall, the 14-day mortality was 23.4%. Multivariate analysis revealed E. meningoseptica bacteremia acquired in an ICU (p = 0.048, odds ratio [OR] 4.23) and presence of effective antibiotic treatment after the availability of culture results (p = 0.049, OR 0.31) were independent predictors of 14-day mortality. The 14-day mortality was higher among patients receiving carbapenems (p = 0.046) than fluoroquinolones or other antimicrobial agents. More than 80% of the isolates tested were susceptible to trimethoprim-sulfamethoxzole, moxifloxacin, and levofloxacin. The MIC(50) and MIC(90) of the isolates to tigecycline and doxycycline were both 4 µg/mL and 8 µg/ml, respectively.


Assuntos
Antibacterianos/uso terapêutico , Bacteriemia/microbiologia , Bacteriemia/patologia , Chryseobacterium/isolamento & purificação , Infecções por Flavobacteriaceae/microbiologia , Infecções por Flavobacteriaceae/patologia , Centros Médicos Acadêmicos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/farmacologia , Bacteriemia/tratamento farmacológico , Criança , Pré-Escolar , Chryseobacterium/efeitos dos fármacos , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Complicações do Diabetes , Feminino , Infecções por Flavobacteriaceae/tratamento farmacológico , Infecções por Flavobacteriaceae/epidemiologia , Humanos , Incidência , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Neoplasias/complicações , Fatores de Risco , Análise de Sobrevida , Taiwan/epidemiologia , Resultado do Tratamento , Adulto Jovem
8.
Shock ; 24 Suppl 1: 120-9, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16374383

RESUMO

The cytokine granulocyte colony-stimulating factor (G-CSF) is a potent endogenous trigger for the release of neutrophils from bone marrow stores and for their activation for enhanced antimicrobial activity. G-CSF has been widely evaluated in preclinical models of acute illness, with generally promising though divergent results. A recombinant G-CSF molecule has recently undergone clinical trials to assess its efficacy as an adjuvant therapy in community-acquired and nosocomial pneumonia, however, these studies failed to provide convincing evidence of benefit. We undertook a systematic review of the published literature reporting the effects of modulation of G-CSF in preclinical in vivo models to determine whether evidence of differential efficacy might explain the disappointing results of human studies and point to disease states that might be more likely to benefit from G-CSF therapy. G-CSF has been evaluated in 86 such studies involving a variety of different models. The strongest evidence of benefit was seen in studies involving intraperitoneal challenge with live organisms; benefit was evident whether the agent was given before or after challenge. G-CSF demonstrates anti-inflammatory activity in models of systemic challenge with viable organisms or endotoxin, but only when the agent is given before challenge; evidence of benefit after challenge was minimal. Preclinical models of intrapulmonary challenge only show efficacy when the cytokine is administered before the infectious challenge, and suggested harm in gram-negative pneumonia resulting from challenge with Escherichia coli or Klebsiella. There is little evidence for therapeutic efficacy in noninfectious models of acute illness. We conclude that the most promising populations for evaluation of G-CSF are neutropenic patients with invasive infection and patients with intra-abdominal infection, particularly those with the syndrome of tertiary, or recurrent, peritonitis. Significant variability in the design and reporting of studies of preclinical models of acute illness precludes more sophisticated data synthesis.


Assuntos
Doenças Transmissíveis/tratamento farmacológico , Infecção Hospitalar/tratamento farmacológico , Infecções por Escherichia coli/tratamento farmacológico , Pneumonia Bacteriana/tratamento farmacológico , Animais , Quimioterapia Adjuvante/métodos , Doenças Transmissíveis/metabolismo , Doenças Transmissíveis/patologia , Infecção Hospitalar/metabolismo , Infecção Hospitalar/patologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos/métodos , Infecções por Escherichia coli/metabolismo , Infecções por Escherichia coli/patologia , Fator Estimulador de Colônias de Granulócitos , Humanos , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Inflamação/patologia , Pneumonia Bacteriana/metabolismo , Pneumonia Bacteriana/patologia , Proteínas Recombinantes
9.
J Chemother ; 16(5): 494-6, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15565919

RESUMO

In the last decade, a remarkable increase in the incidence of nosocomial Gram-negative infections has been observed. These pathogens represent a substantial problem in clinical practice, due to the high resistance profile of most commonly used antibiotics. This phenomenon is surely a co-factor that exposes these susceptible patients to infections caused by selected pathogens like multiresistant Gram-negative rods. A typical example is represented by VAP (ventilator-associated pneumonia) sustained by Acinetobacter spp., Pseudomonas aeruginosa, Bulkolderia cepacia. The Authors describe a case of a central venous cather (CVC)-related Stenotrophomonas maltophilia sepsis in a patient affected by solid tumor, successfully treated with systemic antibiotic therapy associated with "lock therapy". This combination was able to cure the infection, allowing the patient to continue chemotherapy and saving the in situ CVC. The surveillance of CVCs, good adherence to the protocols and guidelines and "good practice" are the cornerstones for the prevention of nosocomial infections.


Assuntos
Antibacterianos/administração & dosagem , Bacteriemia/tratamento farmacológico , Farmacorresistência Bacteriana , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Stenotrophomonas maltophilia/efeitos dos fármacos , Teicoplanina/administração & dosagem , Bacteriemia/diagnóstico , Bacteriemia/etiologia , Bacteriemia/patologia , Cateterismo Venoso Central/efeitos adversos , Infecção Hospitalar/diagnóstico , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/etiologia , Infecção Hospitalar/patologia , Diagnóstico Diferencial , Esquema de Medicação , Contaminação de Equipamentos , Infecções por Bactérias Gram-Negativas/diagnóstico , Infecções por Bactérias Gram-Negativas/etiologia , Infecções por Bactérias Gram-Negativas/patologia , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade
10.
Transpl Infect Dis ; 4 Suppl 3: 38-45, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12486791

RESUMO

Invasive fungal infections have been noted in increasing frequency in immunosuppressed patients and may be due to organisms that are less susceptible or frankly resistant to antifungal agents. Recently, standards have been established for testing both yeasts and moulds for susceptibility to antifungal agents. While these tests are increasingly available for clinical use, clinicians are faced with the challenge of whether these tests offer benefit in terms of management and when they should be obtained. In this review, the relevance of these tests is discussed, as are the clinical data, especially for yeasts, that support their use. In addition, the strategy of identifying yeasts to the species level as a means for predicting susceptibility is also discussed. While susceptibility testing of all fungal isolates is not necessary and not recommended, the judicious use of these tests and the role of the mycology laboratory in assisting in management of invasive fungal infection is also evaluated.


Assuntos
Antifúngicos/uso terapêutico , Fungos/efeitos dos fármacos , Testes de Sensibilidade Microbiana/tendências , Antifúngicos/farmacocinética , Candida/classificação , Candida/efeitos dos fármacos , Candidíase Bucal/tratamento farmacológico , Candidíase Bucal/imunologia , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Relação Dose-Resposta a Droga , Farmacorresistência Fúngica , Fluconazol/uso terapêutico , Humanos , Testes de Sensibilidade Microbiana/normas , Micoses/tratamento farmacológico , Micoses/prevenção & controle
11.
Rev Infect Dis ; 12 Suppl 8: S1065-73, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-2270405

RESUMO

Clinicopathologic correlations for 71 cases of fatal pneumonia in children were determined. The mechanism of death for these patients was multifactorial. Severe pneumonia alone accounted for 11 deaths (15.5%). Pneumonia associated with sepsis occurred in 42 children (59.2%). Heart failure (8.5%), hypovolemia (4.2%), and nosocomial infection (12.6%) were also seen in children with fatal acute lower respiratory tract infection. Extensive consolidation, squamous metaplasia, and hyaline membranes were present in the lungs of these children. Patients with severe disease must receive, in addition to antibiotics for acute episodes, individualized intensive respiratory and supportive care. Since these types of care are not available in poor communities, vaccination against measles and vitamin A supplementation for malnourished children may ameliorate the conditions that appear to predispose these children to severe or fatal disease.


Assuntos
Pneumonia/mortalidade , Doença Aguda , Antibacterianos/uso terapêutico , Infecções Bacterianas/complicações , Pré-Escolar , Infecção Hospitalar/complicações , Infecção Hospitalar/mortalidade , Infecção Hospitalar/patologia , Cardiopatias/complicações , Cardiopatias/patologia , Humanos , Lactente , Pulmão/patologia , Sarampo/complicações , Miocárdio/patologia , Filipinas , Pneumonia/complicações , Pneumonia/patologia , Choque/complicações , Choque/patologia
12.
Am Rev Respir Dis ; 137(2): 265-72, 1988 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3341620

RESUMO

The efficacy of antimicrobial agents applied topically in the oropharynx and trachea with and without intravenous antibiotics in preventing bacterial pneumonias during prolonged (7 to 10 days) mechanical ventilation was studied in 35 baboons, 30 of which had acute lung injury induced by either oleic acid or hyperoxia. In 12 animals receiving no antibiotics, only topical application of polymyxin B (PB), or only intravenous penicillin and gentamicin (IV PCN/GM), moderate or severe pneumonia was found in 81% of lobes examined at necropsy; no lobes were sterile. Pneumonias were polymicrobial in the absence of antibiotics, due to PCN-sensitive organisms in the topical PB group, and due to gram-negative bacilli in the IV PCN/GM group. Combinations of topical PB or GM or both plus IV PCN were highly efficacious in preventing pneumonia in 23 animals as only 15% of the lobes contained moderate to severe pneumonia and 52% of lobes were sterile. In these groups, histologically evident pneumonias were associated with low concentrations of bacteria in lung tissue, principally gram-negative bacilli resistant to the topical agent being used. Resistance to PB appeared to be solely due to selection of intrinsically resistant species, whereas resistance to GM may have developed through additional mechanisms as well. Although this approach to pneumonia prevention is clearly efficacious in this animal model, clinical studies are needed to define the frequency and significance of microbial resistance in human subjects.


Assuntos
Antibacterianos/administração & dosagem , Infecção Hospitalar/prevenção & controle , Pneumonia/prevenção & controle , Administração Tópica , Animais , Bactérias/isolamento & purificação , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Quimioterapia Combinada , Injeções Intravenosas , Pulmão/microbiologia , Pulmão/patologia , Papio , Pneumonia/microbiologia , Pneumonia/patologia , Respiração Artificial , Traqueia/microbiologia
13.
CMAJ ; 134(8): 909-13, 1986 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-3955486

RESUMO

Outbreaks of community-acquired Pseudomonas aeruginosa folliculitis have recently been described in association with health spa whirlpools. In February 1984 we detected an outbreak of Pseudomonas folliculitis among hospital staff and patients using a swimming pool in a newly constructed physiotherapy unit. A rash developed in 5 (45%) of the 11 physiotherapists who had used the pool, as compared with 0 of the 17 who had not (p less than 0 005). Pseudomonas folliculitis also developed in 6 (21%) of 29 outpatients and 4 (33%) of 12 inpatients who had used the facility; Pseudomonas infection of a surgical wound also developed in 1 of the 4 inpatients. The epidemic curve was consistent with a continuing common-source outbreak. P. aeruginosa, serotype O:10, was isolated from three physiotherapists, the patient with an infected surgical wound and the pool. A case-control study of pool users did not identify risk factors for infection, although the physiotherapists had spent longer in the pool than had the patients. After hyperchlorination and structural repairs to the pool, no further cases were identified among pool users. This outbreak is the first reported nosocomial outbreak of Pseudomonas folliculitis. Further investigation is needed to determine the risk of serious Pseudomonas infections in hospitalized patients using physiotherapy pools.


Assuntos
Infecção Hospitalar/etiologia , Surtos de Doenças/epidemiologia , Foliculite/etiologia , Modalidades de Fisioterapia/efeitos adversos , Infecções por Pseudomonas , Piscinas , Adulto , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/patologia , Feminino , Foliculite/epidemiologia , Foliculite/patologia , Humanos , Hidroterapia/efeitos adversos , Masculino , Pessoa de Meia-Idade , Gravidez , Complicações Infecciosas na Gravidez/etiologia , Complicações Infecciosas na Gravidez/patologia , Infecções por Pseudomonas/epidemiologia , Pele/patologia , Infecção da Ferida Cirúrgica/etiologia , Piscinas/normas , Microbiologia da Água
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA